Xenon Pharmaceuticals Inc. (XENE) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 41 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 9, 2026after close 40 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Thu, May 7, 2026after close 37 8-K
Q4 FY2025Thu, Feb 26, 2026after close 57 8-K
Q3 FY2025Mon, Nov 3, 2025after close 34 8-K
Q2 FY2025Mon, Aug 11, 2025after close 42 8-K
Q1 FY2025Mon, May 12, 2025after close 42 8-K
Q4 FY2024Thu, Feb 27, 2025after close 58 8-K

What they guided beta

Q3 FY2026 "Enrollment in Phase 3 X-NOVA2 study of azetukalner in MDD completed with topline data readout now expected in December 2026" exhibit
Q3 FY2026 "Positive Phase 1 data for novel, non-opioid pain programs XEN1701 (Na V 1.7) and XEN1120 (K V 7) presented at IASP World Congress on Pain support initiating Phase 2 proof-of-concept studies in acute pain; studies expected to initiate in H1 2027" exhibit
Q3 FY2026 "“Following the completion of enrollment in X-NOVA2, we are working toward our first Phase 3 data readout in psychiatry with topline results now expected in December 2026." exhibit
Q3 FY2026 "The Company expects multiple new azetukalner and epilepsy data presentations at the American Epilepsy Society (AES) 2026 Annual Meeting, taking place December 4-8, 2026, in Denver, Colorado." exhibit
Q3 FY2026 "The Phase 3 X-TOLE3 study of azetukalner in FS continues to enroll and is intended to support regulatory submissions outside of the U.S. X-TOLE3 enrollment outside of Japan is expected to complete in 2026." exhibit
Q2 FY2026 "Three Phase 3 studies of azetukalner in neuropsychiatry continue to advance, with topline data from X-NOVA2 study in MDD expected H1 2027" exhibit
Q2 FY2026 "Phase 1 studies of novel Na V 1.7 (XEN1701) and K V 7 (XEN1120) candidates expected to complete H2 2026; Phase 1 study underway for second Na V 1.7 (XEN1720) candidate for pain" exhibit
Q2 FY2026 "“We also remain focused on broadening azetukalner’s opportunity to neuropsychiatry and expect topline Phase 3 X-NOVA2 data in the first half of 2027." exhibit
Q2 FY2026 "Xenon remains on track to submit its New Drug Application (NDA) for azetukalner in FOS in the third quarter of 2026, having completed a pre-NDA meeting with the U.S. Food and Drug Administration (FDA)." exhibit
Q2 FY2026 "X-TOLE3 enrollment outside of Japan is expected to complete in 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/XENE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/XENE

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

XENE earnings date badge

HTML

<a href="https://veritasdata.dev/company/XENE/"><img src="https://veritasdata.dev/embed/XENE.svg" alt="XENE earnings date" width="240" height="56"></a>

Markdown

[![XENE earnings date](https://veritasdata.dev/embed/XENE.svg)](https://veritasdata.dev/company/XENE/)

Script

<script async src="https://veritasdata.dev/embed/XENE.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/XENE"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.